Latest News & Updates

Latest Articles
Molecular Subtypes Correlate With Outcomes in RCC
Molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with significant differences seen in overall survival and disease-free survival between groupings.
PUBLISHED: January 16, 2018
Bunn Expands on Significance of Atezolizumab/Bevacizumab Regimen in NSCLC
Paul A. Bunn, Jr, MD, discusses the IMpower150 study and other immunotherapy combinations in NSCLC.
PUBLISHED: January 16, 2018
Hyperprogression Emerges in a Subset of Patients Treated With Immunotherapy
Results from a recent multicenter, retrospective analysis of 242 patients with advanced non–small cell lung cancer (NSCLC) found that 16% developed hyperprogression during anti–PD-1/PD-L1 treatment.
PUBLISHED: January 15, 2018
Markman Proposes Shift in Ovarian Cancer Clinical Trial Paradigm
Maurie Markman, MD, discusses the need to change the paradigm of clinical trials and FDA approvals in ovarian cancer. 
PUBLISHED: January 15, 2018
Preoperative Imaging Remains Integral to Endometrial Cancer Diagnosis
Ingfrid Haldorsen, MD, discusses the role of imaging in the diagnosis of patients with endometrial cancer.
PUBLISHED: January 15, 2018
Latest Peer Exchange Discussions
MDS: The Current Understanding in Molecular Testing and Biomarkers
Panelists James M. Foran, MD, FRCPC, and Azra Raza, MD, provide insight on the current understanding in molecular testing and biomarkers in myelodysplastic syndrome. View Now
ALK-Positive Lung Cancer
Panelists Mark A. Socinski, MD; Gregory J. Riely, MD, PhD; Jared Weiss, MD; Thomas E. Stinchcombe, MD; and Benjamin P. Levy, MD; provide insight on the treatment options in ALK-positive lung cancer. View Now
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Medical Crossfire®: Renal Cell Carcinoma in an Era of Rapid Discovery: Key QuestionsJan 30, 20181.5
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
Publication Bottom Border
Border Publication
x